Patients If GLP-1s work too well, what happens next for metabolic dis... What happens if GLP-1s work too well?
R&D Sponsored The future of cardiometabolic trials: From obesity to outcom... Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO
R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
R&D Sponsored Best practices in cardiometabolic trial design: Planning and... Cardiometabolic disease is not a single entity. It is a broad spectrum of disorders that share common drivers.
R&D Looking ahead to 2026 in biopharma A look forward to trends to come in 2026, including AI-driven drug development, advanced modalities, and cardiometabolic disease therapies.
News Novo Nordisk Foundation gives $75m for R&D 'challenges' The Novo Nordisk Foundation's latest round of R&D funding will go towards projects in biomanufacturing, cardiometabolic diseases, and AI.
News Obesity biotech Kalohexis files confidential IPO Just weeks after forming as a spinout from Endevica Bio, obesity drug developer Kalohexis has filed for an IPO.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
